168 related articles for article (PubMed ID: 11297261)
1. Photodynamic therapy in the canine prostate using motexafin lutetium.
Hsi RA; Kapatkin A; Strandberg J; Zhu T; Vulcan T; Solonenko M; Rodriguez C; Chang J; Saunders M; Mason N; Hahn S
Clin Cancer Res; 2001 Mar; 7(3):651-60. PubMed ID: 11297261
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of motexafin lutetium-mediated intraperitoneal photodynamic therapy in a canine model.
Griffin GM; Zhu T; Solonenko M; Del Piero F; Kapakin A; Busch TM; Yodh A; Polin G; Bauer T; Fraker D; Hahn SM
Clin Cancer Res; 2001 Feb; 7(2):374-81. PubMed ID: 11234893
[TBL] [Abstract][Full Text] [Related]
3. Interstitial photodynamic therapy of the canine prostate using intra-arterial administration of photosensitizer and computerized pulsed light delivery.
Xiao Z; Dickey D; Owen RJ; Tulip J; Moore R
J Urol; 2007 Jul; 178(1):308-13. PubMed ID: 17499802
[TBL] [Abstract][Full Text] [Related]
4. Photodynamic therapy with motexafin lutetium for rectal cancer: a preclinical model in the dog.
Ross HM; Smelstoys JA; Davis GJ; Kapatkin AS; Del Piero F; Reineke E; Wang H; Zhu TC; Busch TM; Yodh AG; Hahn SM
J Surg Res; 2006 Oct; 135(2):323-30. PubMed ID: 16650871
[TBL] [Abstract][Full Text] [Related]
5. Studies of tin ethyl etiopurpurin photodynamic therapy of the canine prostate.
Selman SH; Albrecht D; Keck RW; Brennan P; Kondo S
J Urol; 2001 May; 165(5):1795-801. PubMed ID: 11342978
[TBL] [Abstract][Full Text] [Related]
6. Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer.
Verigos K; Stripp DC; Mick R; Zhu TC; Whittington R; Smith D; Dimofte A; Finlay J; Busch TM; Tochner ZA; Malkowicz S; Glatstein E; Hahn SM
J Environ Pathol Toxicol Oncol; 2006; 25(1-2):373-87. PubMed ID: 16566729
[TBL] [Abstract][Full Text] [Related]
7. Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer.
Du KL; Mick R; Busch TM; Zhu TC; Finlay JC; Yu G; Yodh AG; Malkowicz SB; Smith D; Whittington R; Stripp D; Hahn SM
Lasers Surg Med; 2006 Jun; 38(5):427-34. PubMed ID: 16788929
[TBL] [Abstract][Full Text] [Related]
8. Preclinical studies in normal canine prostate of a novel palladium-bacteriopheophorbide (WST09) photosensitizer for photodynamic therapy of prostate cancers.
Chen Q; Huang Z; Luck D; Beckers J; Brun PH; Wilson BC; Scherz A; Salomon Y; Hetzel FW
Photochem Photobiol; 2002 Oct; 76(4):438-45. PubMed ID: 12405153
[TBL] [Abstract][Full Text] [Related]
9. Lipophilic photosensitizer administration via the prostate arteries for photodynamic therapy of the canine prostate.
Xiao Z; Owen RJ; Liu W; Tulip J; Brown K; Woo T; Moore RB
Photodiagnosis Photodyn Ther; 2010 Jun; 7(2):106-14. PubMed ID: 20510305
[TBL] [Abstract][Full Text] [Related]
10. Spatial distribution of liposome encapsulated tin etiopurpurin dichloride (SnET2) in the canine prostate: implications for computer simulation of photodynamic therapy.
Aniola J; Selman SH; Lilge L; Keck R; Jankun J
Int J Mol Med; 2003 Mar; 11(3):287-91. PubMed ID: 12579328
[TBL] [Abstract][Full Text] [Related]
11. Real-time in situ monitoring of human prostate photodynamic therapy with diffuse light.
Yu G; Durduran T; Zhou C; Zhu TC; Finlay JC; Busch TM; Malkowicz SB; Hahn SM; Yodh AG
Photochem Photobiol; 2006; 82(5):1279-84. PubMed ID: 16696593
[TBL] [Abstract][Full Text] [Related]
12. Interstitial photodynamic therapy in the canine prostate.
Lee LK; Whitehurst C; Chen Q; Pantelides ML; Hetzel FW; Moore JV
Br J Urol; 1997 Dec; 80(6):898-902. PubMed ID: 9439405
[TBL] [Abstract][Full Text] [Related]
13. Reduction of vein graft disease using photodynamic therapy with motexafin lutetium in a rodent isograft model.
Yamaguchi A; Woodburn KW; Hayase M; Robbins RC
Circulation; 2000 Nov; 102(19 Suppl 3):III275-80. PubMed ID: 11082401
[TBL] [Abstract][Full Text] [Related]
14. In vivo photodynamic therapy with the new near-IR absorbing water soluble photosensitizer lutetium texaphyrin and a high intensity pulsed light delivery system.
Kostenich G; Orenstein A; Roitman L; Malik Z; Ehrenberg B
J Photochem Photobiol B; 1997 May; 39(1):36-42. PubMed ID: 9210320
[TBL] [Abstract][Full Text] [Related]
15. Interstitial and transurethral photodynamic therapy of the canine prostate using meso-tetra-(m-hydroxyphenyl) chlorin.
Chang SC; Buonaccorsi G; MacRobert A; Bown SG
Int J Cancer; 1996 Aug; 67(4):555-62. PubMed ID: 8759616
[TBL] [Abstract][Full Text] [Related]
16. In vivo reflectance measurement of optical properties, blood oxygenation and motexafin lutetium uptake in canine large bowels, kidneys and prostates.
Solonenko M; Cheung R; Busch TM; Kachur A; Griffin GM; Vulcan T; Zhu TC; Wang HW; Hahn SM; Yodh AG
Phys Med Biol; 2002 Mar; 47(6):857-73. PubMed ID: 11936174
[TBL] [Abstract][Full Text] [Related]
17. Effects of Pd-bacteriopheophorbide (TOOKAD)-mediated photodynamic therapy on canine prostate pretreated with ionizing radiation.
Huang Z; Chen Q; Trncic N; LaRue SM; Brun PH; Wilson BC; Shapiro H; Hetzel FW
Radiat Res; 2004 Jun; 161(6):723-31. PubMed ID: 15161347
[TBL] [Abstract][Full Text] [Related]
18. Photodynamic therapy using Lu-Tex induces apoptosis in vitro, and its effect is potentiated by angiostatin in retinal capillary endothelial cells.
Renno RZ; Delori FC; Holzer RA; Gragoudas ES; Miller JW
Invest Ophthalmol Vis Sci; 2000 Nov; 41(12):3963-71. PubMed ID: 11053300
[TBL] [Abstract][Full Text] [Related]
19. Photodynamic therapy with motexafin lutetium (Lu-Tex) reduces experimental graft coronary artery disease.
Yamaguchi A; Woodburn KW; Hayase M; Hoyt G; Robbins RC
Transplantation; 2001 Jun; 71(11):1526-32. PubMed ID: 11435960
[TBL] [Abstract][Full Text] [Related]
20. Optical characteristics of the canine prostate at 665 nm sensitized with tin etiopurpurin dichloride: need for real-time monitoring of photodynamic therapy.
Jankun J; Lilge L; Douplik A; Keck RW; Pestka M; Szkudlarek M; Stevens PJ; Lee RJ; Selman SH
J Urol; 2004 Aug; 172(2):739-43. PubMed ID: 15247773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
